Viking Therapeutics Initiates SUNRISE Phase 3 Clinical Program For Oral VK2735 Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors

Benzinga

2026.10.14 11:09 (GMT+0)

Benzingaで開く